

Title : MORPHINE ANESTHESIA IN PATIENTS WITH LIVER FAILURE

Authors : C.C. Hug, Jr., M.D., Ph.D., J.A. Aldrete, M.D., J.F. Sampson, M.D.
and M.R. Murphy, M.D.

Affiliation: Departments of Anesthesiology, Emory University Medical School, Atlanta, Georgia 30322 and University of Colorado Medical Center, Denver, Colorado 80262

INTRODUCTION. Morphine (M) is administered in large doses for anesthetic purposes. M "anesthesia" is used for patients with abnormal liver function in order to avoid volatile anesthetics which may be hepatotoxic. One concern about this use of M is the prolongation of its duration of action, because the primary mechanism of M elimination in man is hepatic biotransformation to morphine-glucuronide.¹

METHODS. Five patients with end-stage liver disease were studied during the intra-operative period of homograft liver transplantation. They were informed and gave their written consent to this institutionally approved study. A single dose of M ($0.67 \pm .04$ mg/kg) was administered iv at a rate of 5-10 mg/min. Arterial blood was sampled intermittently and urine collected continuously over the next 24 hours. Plasma and urine samples were analyzed specifically for unchanged M and for total M (i.e., unchanged M and its metabolites).² In addition, some urine samples were incubated with β -glucuronidase in order to estimate specifically their content of morphine-glucuronide. The diseased liver was removed within the first 2 hours and revascularization of the donor liver occurred 6 or more hours after M administration.

RESULTS. Plasma concentrations of unchanged M ranged from 45 to 308 ng/ml in samples taken 2 hours after the iv dose. More than 98% of the dose left the plasma compartment by 2 hours. The subsequent decline of M levels was much slower with an apparent half-time in excess of 5 hours between 6 and 12 hours after M injection (figure). M metabolites, calculated as the difference between unchanged and total M, were evident 2 hours after injection and their proportion increased progressively with time both before and after revascularization of the newly transplanted liver. Urine collected over the first 6 hours following M administration and before revascularization of the donor liver contained $32 \pm 7\%$ of the administered dose predominately as conjugated metabolites (i.e., 72-90% of the total M in urine). Incubation of selected urine samples with β -glucuronidase indicated that essentially all of the conjugated metabolites were glucuronides.

DISCUSSION. The initially rapid clearance of 98% of the iv dose of M from plasma presumably resulted from extensive uptake of the unchanged drug by body tissues. In this regard, patients with liver failure resembled normal men in which the distributive phase of M disposition was essentially complete within 2 hours.^{2,3} Nevertheless, the absolute levels of M in plasma 2 hours after injection in liver-failure patients were higher than the

50 ng/ml estimated for a 0.7 mg/kg dose from studies in patients with normal liver function.²⁻⁴ These higher plasma levels and the slower subsequent clearance of M from plasma are to be expected in the absence of hepatic function. The notable finding of this study is that M metabolism, especially glucuronide-conjugation, occurred in spite of liver failure. This observation indicates that there are nonhepatic sites of M biotransformation in man. It also means that the anesthesiologist can anticipate eventual recovery from the effects of M administered to such patients. Although it is not possible to make precise estimates of dosage requirements from this study, the data suggest that the initial dose of M will be somewhat less than for patients with normal liver function. The need for maintenance doses will be markedly reduced both in amount and frequency of administration.

This study was supported in part by NIH grant DA-00808.

REFERENCES

1. Way EL, Adler TK: The pharmacologic implications of the fate of morphine and its surrogates. *Pharmacol Rev* 12:383-446, 1960.
2. Hug CC Jr.: Plasma levels of morphine in anesthetized patients. *Pharmacologist* 17:175, 1975.
3. Stanski DR, Greenblatt DJ, Lowenstein E: Kinetics of intravenous and intramuscular morphine. *Clin Pharmacol Ther* 24:52-59, 1978.
4. Hug CC Jr.: Pharmacokinetics of morphine during cardiac surgery. ASA Annual Meeting, 1978, pp 305-306.




Figure: Plasma concentrations of unchanged and total M in patients undergoing liver transplantation. P values were determined by Student's t-test (n=5).